Loading stock data…
$26.68+0.54 (+2.07%)
CeriBell, Inc.
CBLL in the Healthcare sector is trading at $26.28 with a market capitalization of $907M. Wall Street consensus targets $28.57 (7 analysts), implying a +8.7% move over the next 12 months. The stock is currently near its 52-week high of $26.62, remaining 28.3% above its 200-day moving average. On fundamentals, Piotroski 3/9 flags weak fundamentals, Altman Z in the safe zone. The Whystock Score of 85/100 reflects bullish alignment across trend, valuation and analyst targets.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $28.10M↑ | $26.49M↑ | $24.78M↑ | $22.59M↑ | $21.20M |
| Gross Profit | $25.94M↑ | $23.12M↑ | $21.64M↑ | $19.94M↑ | $18.68M |
| Operating Income | -$19.98M↑ | -$20.75M↓ | -$14.60M↑ | -$14.65M↑ | -$14.95M |
| Net Income | -$19.27M↑ | -$19.74M↓ | -$13.53M↓ | -$13.46M↑ | -$13.64M |
CeriBell, Inc. operates as a medical technology company in the United States. It develops the Ceribell System, a novel and point-of-care EEG platform specifically designed to address the unmet needs of patients in the acute care setting. The company ...